Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DJA64B
|
|||
Drug Name |
TC-510
|
|||
Drug Type |
Cell therapy
|
|||
Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 1/2 | [1] | |
Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1/2 | [1] | ||
Company |
TCR2 Therapeutics
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Mesothelin (MSLN) | Target Info | . | [2] |
NetPath Pathway | TCR Signaling Pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT05451849) A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer. U.S.National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of TCR2 Therapeutics |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.